Dr. Alexandre Akoulitchev is the co-founder and Chief Scientific Officer of Oxford BioDynamics Plc, a biotechnology company specializing in epigenetic biomarker discovery. He leads the development of the EpiSwitch™ platform, which identifies chromosome conformation signatures to aid in diagnostics and patient stratification across various diseases, including cancer, autoimmune, and neurodegenerative disorders.

Dr. Akoulitchev's academic background includes a PhD in cell biology from University College London, with research conducted at the Imperial Cancer Research Fund Laboratories. He has held research positions at institutions such as the Robert Wood Johnson Medical School in New Jersey and the University of Oxford, where he established a laboratory at the Sir William Dunn School of Pathology.